Atiprimod: A multi-functional drug candidate for myeloid and other malignancies

Leukemia Research

Volumn 31, Issue 1, 2007, Pages 9-10

  Shailubhai, Kunwar ^a,b  

^a Institute for Hepatitis and Virus Research   (United States)

^b Callisto Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATIPRIMOD; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE 2;

CANCER; DOWN REGULATION; DRUG ACTIVITY; EDITORIAL; GENE OVEREXPRESSION; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL DIVISION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASMS; SPIRO COMPOUNDS; TRETINOIN;

EID: 33750736648     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.06.007     Document Type: Editorial

References (13)

1. Shailubhai K., Dheer S.K., Picker D., Sausville E., Kaur G., and Jacob G.S. Atiprimod is a novel anti-angiogenic and anti-cancer drug candidate. Jr Exp Ther Oncol 4 (2004) 267-279
2. Amit-Vazina M., Shishodia S., Harris D., Van Q., Wang M., Weber D., et al. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 93 (2005) 70-80
3. Hamasaki M., Hideshima T., Tassone P., Neri P., Ishitsuka K., Yasui H., et al. Azaspirane (N,N-diethyl-8,8-dipropyl-2-azaspiro [4,5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 105 (2005) 4470-4486 [Epub 10 February 2005]
4. Tassone P., Neri P., Carrasco D.R., Burger R., Goldmacher V.S., Fram R., et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 106 (2005) 713-716 [Epub 7 April 2005]
5. Braiteh F.S., Yao J., Camacho L.H., Ng C., Hong D.S., Dhillon N., et al. Phase I study of the safety and efficacy of atiprimod, a novel azaspirine, for patients with advanced cancer. Proceedings of the ASCO annual meeting. June 2-6 (2006)
6. Faderi S., Ferrajoli A., Harris D., Van Q., Kantarjian H., and Estrov Z. Atiprimod blocks phosphorylation of Jak-STAT and inhibits proliferation of acute myloid leukemia (AML) cells. Leukemia Res 31 (2007) 91-95
7. Darnell J.E. The JAK-STAT pathway: summary of initial studies and recent advances. Recent Prog Horm Res 51 (1996) 391-403 [Discussion 403-4]
8. Ungureanu D., Saharinen P., Junttila I., Hilton D.J., and Silvennoinen O. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 22 10 (2002) 3316-3326
9. Schuringa J.J., Wierenga A.T., Kruijer W., and Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 95 12 (2000) 3765-3770
10. Koistinen P., Saily M., Poromaa N., and Savolainen E.R. Complex effects of interleukin 6 on clonogenic blast cell growth in acute myeloblastic leukemia. Acta Haematol 98 1 (1997) 14-21
11. Kiyoi H., and Naoe T. FLT3 mutations in acute myeloid leukemia. Meth Mol Med 125 (2006) 189-197
12. Martelli A.M., Nyakern M., Tabellini G., Bortul R., Tazzari P.L., Evangelisti C., et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20 (2006) 911-928
13. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21 (2002) 2000-2008